Swedish biotech Epigenica has announced a new agreement with the National Genomics Infrastructure (NGI), where NGI Stockholm will become the first official core laboratory and service provider globally to offer Epigenica's EpiFinder platform.
As the first certified service provider, NGI will now deliver end-to-end workflows using both EpiFinder cNuc and EpiFinder GenomePro for histone and DNA methylation profiling.
The new offerings will enable scalable, reproducible and highly robust epigenomic insights for projects of any size.
"Partnering with NGI marks the first step in scaling access to our epigenomic platforms," said Mohamad Takwa, CEO of Epigenica.
"By working with one of Europe's leading genomics infrastructures, we are not only expanding availability of EpiFinder GenomePro and EpiFinder cNUC, but also establishing a model for how these technologies can be deployed more broadly."
This collaboration lays the foundation for a growing network of partners and will support more consistent, high-quality epigenomic research at scale.
NGI users will also gain access to full project support, including study design consultation, sample preparation, sequencing and downstream analysis, through the collaboration.
"We are thrilled to be the first core facility certified to deliver Epigenica's EpiFinder technologies," added Anja Mezger, Head of Unit at NGI in Stockholm.
These platforms fill critical needs for researchers seeking high-resolution epigenomic insights through streamlined workflows.
"With EpiFinder GenomePro and cNuc, we can offer even greater depth and capability within our service portfolio."
Epigenica said in its statement that the collaboration was part of a broader strategy to build a global network of dedicated certified service providers that can deliver high-quality epigenomic data.
It added that further partner sites will be announced in due course as adoption of EpiFinder GenomePro and cNuc expands across academia, biopharma and pharmaceutical research.